Edwin Liu
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Celiac Disease | 63 | 2025 | 295 | 10.560 |
Why?
| | Autoantibodies | 48 | 2024 | 1474 | 3.120 |
Why?
| | Transglutaminases | 28 | 2025 | 156 | 3.030 |
Why?
| | HLA-DQ Antigens | 11 | 2019 | 178 | 1.890 |
Why?
| | Diet, Gluten-Free | 11 | 2025 | 48 | 1.650 |
Why?
| | Autoimmune Diseases | 8 | 2019 | 465 | 1.550 |
Why?
| | Autoimmunity | 23 | 2024 | 906 | 1.520 |
Why?
| | GTP-Binding Proteins | 12 | 2025 | 151 | 1.400 |
Why?
| | Diabetes Mellitus, Type 1 | 47 | 2024 | 3788 | 1.370 |
Why?
| | Genetic Predisposition to Disease | 21 | 2024 | 2368 | 1.260 |
Why?
| | Peptide Fragments | 15 | 2008 | 698 | 1.240 |
Why?
| | Insulin | 24 | 2009 | 2458 | 1.210 |
Why?
| | Glutens | 10 | 2023 | 59 | 0.950 |
Why?
| | HLA-DR3 Antigen | 3 | 2015 | 78 | 0.890 |
Why?
| | Islets of Langerhans | 17 | 2017 | 803 | 0.860 |
Why?
| | Rett Syndrome | 1 | 2024 | 40 | 0.840 |
Why?
| | HLA-DR Antigens | 5 | 2017 | 227 | 0.740 |
Why?
| | Gastrointestinal Diseases | 1 | 2024 | 206 | 0.740 |
Why?
| | Insulin Antibodies | 11 | 2013 | 103 | 0.740 |
Why?
| | Nutrition Therapy | 1 | 2020 | 35 | 0.640 |
Why?
| | Genetic Testing | 6 | 2015 | 463 | 0.620 |
Why?
| | Child | 45 | 2025 | 22313 | 0.620 |
Why?
| | Pyrrolidinones | 1 | 2019 | 30 | 0.620 |
Why?
| | Child, Preschool | 32 | 2025 | 11462 | 0.590 |
Why?
| | Mice, Inbred NOD | 22 | 2013 | 599 | 0.560 |
Why?
| | Patient Compliance | 2 | 2023 | 607 | 0.550 |
Why?
| | Down Syndrome | 2 | 2023 | 505 | 0.530 |
Why?
| | Anticonvulsants | 1 | 2019 | 223 | 0.520 |
Why?
| | Immunoglobulin A | 9 | 2025 | 214 | 0.520 |
Why?
| | Mass Screening | 8 | 2024 | 1300 | 0.520 |
Why?
| | Diabetes Mellitus, Experimental | 3 | 2006 | 196 | 0.480 |
Why?
| | Humans | 86 | 2025 | 140898 | 0.450 |
Why?
| | Infant | 27 | 2025 | 9790 | 0.450 |
Why?
| | Epilepsy | 1 | 2019 | 347 | 0.450 |
Why?
| | Intestinal Mucosa | 4 | 2025 | 628 | 0.440 |
Why?
| | Anaphylaxis | 3 | 2004 | 107 | 0.420 |
Why?
| | Caregivers | 1 | 2022 | 940 | 0.400 |
Why?
| | Poly I-C | 4 | 2008 | 63 | 0.400 |
Why?
| | Depression | 2 | 2022 | 1487 | 0.390 |
Why?
| | Female | 58 | 2025 | 75540 | 0.380 |
Why?
| | Adolescent | 25 | 2025 | 22027 | 0.380 |
Why?
| | Gliadin | 3 | 2018 | 12 | 0.370 |
Why?
| | Radioimmunoassay | 3 | 2016 | 169 | 0.360 |
Why?
| | Polymorphism, Single Nucleotide | 7 | 2024 | 2128 | 0.360 |
Why?
| | Prospective Studies | 21 | 2024 | 7749 | 0.350 |
Why?
| | Follow-Up Studies | 12 | 2024 | 5194 | 0.350 |
Why?
| | Male | 49 | 2025 | 69893 | 0.350 |
Why?
| | Telemedicine | 1 | 2020 | 886 | 0.350 |
Why?
| | Jejunum | 1 | 2011 | 32 | 0.340 |
Why?
| | Biopsy | 11 | 2025 | 1069 | 0.330 |
Why?
| | Adjuvants, Immunologic | 3 | 2007 | 238 | 0.330 |
Why?
| | Clinical Laboratory Techniques | 1 | 2011 | 96 | 0.320 |
Why?
| | Quality of Life | 5 | 2024 | 3005 | 0.310 |
Why?
| | Sensitivity and Specificity | 9 | 2017 | 1968 | 0.310 |
Why?
| | Nutritionists | 2 | 2020 | 19 | 0.300 |
Why?
| | Risk Factors | 17 | 2024 | 10430 | 0.290 |
Why?
| | Luminescent Measurements | 2 | 2020 | 74 | 0.290 |
Why?
| | Liver Failure, Acute | 2 | 2008 | 66 | 0.290 |
Why?
| | Dietary Proteins | 2 | 2019 | 135 | 0.280 |
Why?
| | Laboratories | 1 | 2009 | 107 | 0.280 |
Why?
| | Interferon-alpha | 2 | 2005 | 196 | 0.260 |
Why?
| | Wheat Hypersensitivity | 1 | 2007 | 4 | 0.260 |
Why?
| | Mice | 32 | 2013 | 18057 | 0.260 |
Why?
| | Poly A-U | 1 | 2006 | 4 | 0.260 |
Why?
| | Immune Tolerance | 4 | 2013 | 374 | 0.250 |
Why?
| | Europe | 6 | 2017 | 406 | 0.250 |
Why?
| | T-Lymphocytes | 7 | 2008 | 2003 | 0.240 |
Why?
| | Serologic Tests | 4 | 2021 | 54 | 0.240 |
Why?
| | Time Factors | 10 | 2025 | 6944 | 0.230 |
Why?
| | HLA Antigens | 5 | 2019 | 234 | 0.230 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.220 |
Why?
| | Dyspepsia | 1 | 2024 | 10 | 0.220 |
Why?
| | Predictive Value of Tests | 8 | 2025 | 2062 | 0.220 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2010 | 851 | 0.210 |
Why?
| | CD4 Antigens | 2 | 2003 | 141 | 0.210 |
Why?
| | Antibodies | 3 | 2014 | 411 | 0.210 |
Why?
| | Electrochemical Techniques | 2 | 2021 | 53 | 0.210 |
Why?
| | Gastrointestinal Agents | 1 | 2024 | 66 | 0.210 |
Why?
| | Genotype | 7 | 2019 | 1862 | 0.200 |
Why?
| | Animals | 34 | 2015 | 37579 | 0.200 |
Why?
| | Autoantigens | 6 | 2009 | 425 | 0.200 |
Why?
| | Peptides | 3 | 2018 | 979 | 0.200 |
Why?
| | Abdominal Pain | 1 | 2024 | 144 | 0.200 |
Why?
| | Diet | 4 | 2019 | 1269 | 0.200 |
Why?
| | Endosonography | 1 | 2024 | 153 | 0.200 |
Why?
| | Biomarkers | 7 | 2025 | 4175 | 0.190 |
Why?
| | Mice, Inbred BALB C | 8 | 2009 | 1271 | 0.190 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2006 | 719 | 0.180 |
Why?
| | Seasons | 1 | 2024 | 542 | 0.180 |
Why?
| | Ileal Diseases | 1 | 2001 | 12 | 0.180 |
Why?
| | Short Bowel Syndrome | 1 | 2001 | 27 | 0.180 |
Why?
| | Catheterization | 2 | 2001 | 182 | 0.180 |
Why?
| | Colonic Diseases | 1 | 2001 | 36 | 0.180 |
Why?
| | Comorbidity | 2 | 2024 | 1658 | 0.170 |
Why?
| | Proportional Hazards Models | 7 | 2019 | 1261 | 0.170 |
Why?
| | Mice, Transgenic | 7 | 2013 | 2176 | 0.170 |
Why?
| | Dietetics | 1 | 2020 | 27 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2022 | 552 | 0.160 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 91 | 0.160 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2008 | 1112 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2024 | 578 | 0.160 |
Why?
| | Incidence | 5 | 2022 | 2782 | 0.150 |
Why?
| | Infant, Newborn | 8 | 2019 | 6257 | 0.150 |
Why?
| | Vaccines | 1 | 2004 | 405 | 0.150 |
Why?
| | Enterovirus | 1 | 2019 | 85 | 0.150 |
Why?
| | Probiotics | 1 | 2019 | 57 | 0.150 |
Why?
| | Duodenum | 3 | 2023 | 74 | 0.150 |
Why?
| | Immunization | 4 | 2007 | 405 | 0.140 |
Why?
| | Risk | 3 | 2019 | 903 | 0.140 |
Why?
| | Prevalence | 3 | 2023 | 2780 | 0.140 |
Why?
| | Diabetes Mellitus | 2 | 2007 | 1072 | 0.140 |
Why?
| | Risk Assessment | 8 | 2020 | 3484 | 0.140 |
Why?
| | Adoptive Transfer | 4 | 2008 | 223 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2022 | 359 | 0.140 |
Why?
| | Antibodies, Monoclonal | 2 | 2009 | 1471 | 0.140 |
Why?
| | Anxiety | 2 | 2022 | 1076 | 0.130 |
Why?
| | United States | 9 | 2025 | 15195 | 0.130 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2016 | 14 | 0.130 |
Why?
| | Parents | 2 | 2024 | 1440 | 0.120 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 2 | 2013 | 50 | 0.120 |
Why?
| | Feces | 1 | 2019 | 493 | 0.120 |
Why?
| | Cesarean Section | 1 | 2018 | 213 | 0.120 |
Why?
| | Anorexia Nervosa | 1 | 2017 | 78 | 0.120 |
Why?
| | Gastroenteritis | 1 | 2016 | 68 | 0.120 |
Why?
| | Epitopes, T-Lymphocyte | 2 | 2007 | 183 | 0.120 |
Why?
| | Retrospective Studies | 7 | 2025 | 16315 | 0.120 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5645 | 0.120 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 5931 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2020 | 772 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2006 | 4407 | 0.110 |
Why?
| | HLA-DP beta-Chains | 1 | 2015 | 91 | 0.110 |
Why?
| | HLA-DR4 Antigen | 1 | 2014 | 77 | 0.110 |
Why?
| | Immunoglobulin G | 3 | 2021 | 897 | 0.110 |
Why?
| | Case-Control Studies | 6 | 2019 | 3578 | 0.110 |
Why?
| | Weight Gain | 1 | 2017 | 537 | 0.100 |
Why?
| | Homozygote | 1 | 2014 | 201 | 0.100 |
Why?
| | ROC Curve | 3 | 2013 | 589 | 0.100 |
Why?
| | Adaptor Proteins, Signal Transducing | 2 | 2013 | 438 | 0.100 |
Why?
| | Mice, Knockout | 8 | 2009 | 3064 | 0.100 |
Why?
| | International Cooperation | 2 | 2016 | 195 | 0.100 |
Why?
| | Clonal Anergy | 1 | 2013 | 52 | 0.100 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2012 | 11 | 0.100 |
Why?
| | Child Development | 1 | 2017 | 496 | 0.100 |
Why?
| | Mice, SCID | 4 | 2008 | 365 | 0.100 |
Why?
| | Cohort Studies | 6 | 2025 | 5789 | 0.100 |
Why?
| | Young Adult | 5 | 2024 | 13646 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2013 | 159 | 0.100 |
Why?
| | B-Lymphocyte Subsets | 1 | 2013 | 78 | 0.090 |
Why?
| | Amino Acid Sequence | 3 | 2008 | 2152 | 0.090 |
Why?
| | Receptors, Calcitriol | 1 | 2012 | 55 | 0.090 |
Why?
| | Protein Precursors | 2 | 2003 | 134 | 0.090 |
Why?
| | Health Services Accessibility | 1 | 2020 | 1020 | 0.090 |
Why?
| | Sweden | 3 | 2017 | 104 | 0.090 |
Why?
| | Kaplan-Meier Estimate | 1 | 2014 | 907 | 0.090 |
Why?
| | Breast Feeding | 1 | 2015 | 442 | 0.090 |
Why?
| | Bone Density | 1 | 2015 | 495 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1643 | 0.090 |
Why?
| | Colorado | 2 | 2024 | 4597 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2024 | 11125 | 0.090 |
Why?
| | Heterozygote | 2 | 2016 | 308 | 0.090 |
Why?
| | Adenoviridae | 2 | 2019 | 200 | 0.090 |
Why?
| | Proinsulin | 3 | 2008 | 52 | 0.080 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1856 | 0.080 |
Why?
| | Plant Proteins | 1 | 2011 | 111 | 0.080 |
Why?
| | Immunoglobulin E | 2 | 2021 | 331 | 0.080 |
Why?
| | Monitoring, Immunologic | 1 | 2009 | 22 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2015 | 679 | 0.080 |
Why?
| | Mice, Inbred C57BL | 8 | 2013 | 5895 | 0.080 |
Why?
| | Prothrombin Time | 2 | 2008 | 35 | 0.080 |
Why?
| | Reproducibility of Results | 3 | 2024 | 3336 | 0.080 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2006 | 915 | 0.080 |
Why?
| | Radioligand Assay | 1 | 2009 | 37 | 0.070 |
Why?
| | Bilirubin | 2 | 2008 | 90 | 0.070 |
Why?
| | Prediabetic State | 3 | 2009 | 251 | 0.070 |
Why?
| | Ammonia | 2 | 2008 | 61 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1395 | 0.070 |
Why?
| | Decision Support Techniques | 1 | 2013 | 429 | 0.070 |
Why?
| | Intracellular Fluid | 1 | 2008 | 26 | 0.070 |
Why?
| | Vaccines, DNA | 1 | 2008 | 32 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2008 | 2898 | 0.070 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2008 | 12 | 0.070 |
Why?
| | Injections, Subcutaneous | 3 | 2004 | 165 | 0.070 |
Why?
| | Spleen | 3 | 2007 | 522 | 0.070 |
Why?
| | Biopsy, Needle | 2 | 2011 | 187 | 0.070 |
Why?
| | Disease Progression | 6 | 2016 | 2791 | 0.070 |
Why?
| | Hyperglycemia | 2 | 2008 | 363 | 0.070 |
Why?
| | Cholera Toxin | 1 | 2007 | 31 | 0.070 |
Why?
| | B7-1 Antigen | 2 | 2004 | 57 | 0.070 |
Why?
| | Histocompatibility Antigens | 1 | 2008 | 108 | 0.070 |
Why?
| | Disease Susceptibility | 2 | 2020 | 352 | 0.060 |
Why?
| | Self-Help Groups | 1 | 2007 | 37 | 0.060 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 200 | 0.060 |
Why?
| | Adult | 8 | 2023 | 39134 | 0.060 |
Why?
| | Genes, RAG-1 | 1 | 2006 | 12 | 0.060 |
Why?
| | Blood Glucose | 3 | 2006 | 2273 | 0.060 |
Why?
| | Interferon-gamma | 2 | 2008 | 789 | 0.060 |
Why?
| | Crosses, Genetic | 1 | 2006 | 133 | 0.060 |
Why?
| | Mice, Mutant Strains | 1 | 2006 | 306 | 0.060 |
Why?
| | Antibody Formation | 1 | 2007 | 297 | 0.060 |
Why?
| | Logistic Models | 3 | 2017 | 2088 | 0.060 |
Why?
| | Education, Continuing | 1 | 2006 | 41 | 0.060 |
Why?
| | Intestine, Small | 1 | 2007 | 157 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2056 | 0.060 |
Why?
| | Pediatrics | 2 | 2016 | 1097 | 0.060 |
Why?
| | Age Factors | 3 | 2017 | 3278 | 0.060 |
Why?
| | Isoelectric Point | 1 | 2004 | 23 | 0.060 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 10 | 0.060 |
Why?
| | Antibodies, Heterophile | 1 | 2004 | 13 | 0.050 |
Why?
| | CD3 Complex | 1 | 2024 | 106 | 0.050 |
Why?
| | Survival Rate | 2 | 2007 | 1962 | 0.050 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2917 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 857 | 0.050 |
Why?
| | Immunity, Mucosal | 1 | 2004 | 96 | 0.050 |
Why?
| | Pancreatitis, Chronic | 1 | 2024 | 61 | 0.050 |
Why?
| | Canada | 1 | 2025 | 419 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2005 | 172 | 0.050 |
Why?
| | Cyclophosphamide | 1 | 2003 | 256 | 0.050 |
Why?
| | Genetic Markers | 2 | 2015 | 342 | 0.050 |
Why?
| | Gene-Environment Interaction | 1 | 2024 | 187 | 0.050 |
Why?
| | Nerve Block | 1 | 2024 | 97 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2004 | 556 | 0.050 |
Why?
| | Epitopes | 1 | 2005 | 477 | 0.050 |
Why?
| | Ultrasonography, Interventional | 1 | 2024 | 155 | 0.050 |
Why?
| | Enkephalins | 1 | 2002 | 19 | 0.050 |
Why?
| | Pyridinium Compounds | 1 | 2002 | 29 | 0.050 |
Why?
| | Anemia, Pernicious | 1 | 2002 | 7 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1491 | 0.050 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2002 | 18 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2008 | 2604 | 0.050 |
Why?
| | Thyroid Diseases | 1 | 2002 | 34 | 0.050 |
Why?
| | Animals, Newborn | 1 | 2004 | 866 | 0.050 |
Why?
| | Addison Disease | 1 | 2002 | 42 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 369 | 0.050 |
Why?
| | Immunotherapy | 1 | 2007 | 643 | 0.050 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2002 | 71 | 0.050 |
Why?
| | Oligopeptides | 1 | 2003 | 275 | 0.050 |
Why?
| | Paracentesis | 1 | 2001 | 14 | 0.040 |
Why?
| | Gastroschisis | 1 | 2001 | 32 | 0.040 |
Why?
| | Ascites | 1 | 2001 | 47 | 0.040 |
Why?
| | Diagnostic Techniques, Radioisotope | 1 | 2021 | 9 | 0.040 |
Why?
| | Immunoglobulin D | 1 | 2021 | 30 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2001 | 158 | 0.040 |
Why?
| | Prognosis | 2 | 2008 | 4060 | 0.040 |
Why?
| | Psychometrics | 1 | 2024 | 734 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 437 | 0.040 |
Why?
| | Gene Expression | 1 | 2005 | 1490 | 0.040 |
Why?
| | Asymptomatic Diseases | 1 | 2021 | 92 | 0.040 |
Why?
| | Survival Analysis | 1 | 2003 | 1320 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 858 | 0.040 |
Why?
| | Algorithms | 1 | 2008 | 1763 | 0.040 |
Why?
| | Immunoglobulin M | 1 | 2021 | 287 | 0.040 |
Why?
| | Diet Records | 1 | 2019 | 83 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 283 | 0.040 |
Why?
| | Colonoscopy | 1 | 2001 | 250 | 0.040 |
Why?
| | Infant Formula | 1 | 2019 | 71 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2007 | 1536 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1815 | 0.040 |
Why?
| | Longitudinal Studies | 2 | 2017 | 2920 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5594 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 181 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2017 | 123 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 479 | 0.030 |
Why?
| | Behavior Therapy | 1 | 2020 | 282 | 0.030 |
Why?
| | Rotavirus | 1 | 2016 | 20 | 0.030 |
Why?
| | Drug Utilization | 1 | 2017 | 166 | 0.030 |
Why?
| | Rotavirus Vaccines | 1 | 2016 | 42 | 0.030 |
Why?
| | Disease Management | 1 | 2020 | 628 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2002 | 468 | 0.030 |
Why?
| | Reference Values | 2 | 2011 | 803 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2015 | 1598 | 0.030 |
Why?
| | Phenotype | 3 | 2015 | 3172 | 0.030 |
Why?
| | China | 1 | 2016 | 220 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 766 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2017 | 246 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1703 | 0.030 |
Why?
| | Aggression | 1 | 2017 | 194 | 0.030 |
Why?
| | DNA Primers | 2 | 2008 | 508 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2015 | 117 | 0.030 |
Why?
| | Family Health | 1 | 2016 | 194 | 0.030 |
Why?
| | Protective Factors | 1 | 2015 | 96 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2019 | 566 | 0.030 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2020 | 670 | 0.030 |
Why?
| | Aging | 1 | 2005 | 1917 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 85 | 0.030 |
Why?
| | Vaccination | 1 | 2003 | 1467 | 0.030 |
Why?
| | Gene Frequency | 1 | 2015 | 492 | 0.030 |
Why?
| | Sleep Wake Disorders | 1 | 2017 | 304 | 0.020 |
Why?
| | Immunohistochemistry | 2 | 2011 | 1726 | 0.020 |
Why?
| | Intestines | 1 | 2015 | 355 | 0.020 |
Why?
| | Base Sequence | 2 | 2008 | 2169 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2016 | 712 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1310 | 0.020 |
Why?
| | Respiratory Tract Infections | 1 | 2016 | 383 | 0.020 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2013 | 132 | 0.020 |
Why?
| | Administration, Oral | 2 | 2004 | 802 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2013 | 244 | 0.020 |
Why?
| | Glutamate Decarboxylase | 1 | 2012 | 166 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2374 | 0.020 |
Why?
| | Sex Factors | 1 | 2017 | 2051 | 0.020 |
Why?
| | Species Specificity | 2 | 2004 | 577 | 0.020 |
Why?
| | T-Lymphocyte Subsets | 1 | 2013 | 414 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 777 | 0.020 |
Why?
| | Models, Genetic | 1 | 2013 | 587 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2010 | 61 | 0.020 |
Why?
| | Age Distribution | 1 | 2011 | 397 | 0.020 |
Why?
| | Radioimmunoprecipitation Assay | 1 | 2009 | 6 | 0.020 |
Why?
| | Sex Distribution | 1 | 2011 | 381 | 0.020 |
Why?
| | Microchemistry | 1 | 2009 | 19 | 0.020 |
Why?
| | Staphylococcal Protein A | 1 | 2009 | 14 | 0.020 |
Why?
| | Pregnancy | 2 | 2018 | 7035 | 0.020 |
Why?
| | Antigens, CD20 | 1 | 2009 | 35 | 0.020 |
Why?
| | Sialic Acid Binding Ig-like Lectin 2 | 1 | 2009 | 18 | 0.020 |
Why?
| | Europium | 1 | 2009 | 2 | 0.020 |
Why?
| | Biotinylation | 1 | 2009 | 32 | 0.020 |
Why?
| | Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
| | Registries | 1 | 2017 | 2143 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2001 | 2813 | 0.020 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2008 | 85 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2013 | 1141 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 1 | 2008 | 23 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 267 | 0.020 |
Why?
| | Conserved Sequence | 1 | 2008 | 238 | 0.020 |
Why?
| | Plasmids | 1 | 2008 | 365 | 0.020 |
Why?
| | Cross-Priming | 1 | 2007 | 16 | 0.020 |
Why?
| | Cell Transplantation | 1 | 2007 | 39 | 0.020 |
Why?
| | Administration, Intranasal | 1 | 2007 | 91 | 0.020 |
Why?
| | Metabolic Networks and Pathways | 1 | 2008 | 184 | 0.020 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 335 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2007 | 293 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2013 | 4199 | 0.010 |
Why?
| | Integrin alpha Chains | 1 | 2004 | 24 | 0.010 |
Why?
| | Polyethylene Glycols | 1 | 2009 | 639 | 0.010 |
Why?
| | Environmental Health | 1 | 2004 | 39 | 0.010 |
Why?
| | Maternal-Fetal Exchange | 1 | 2004 | 170 | 0.010 |
Why?
| | T-Box Domain Proteins | 1 | 2003 | 102 | 0.010 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2003 | 65 | 0.010 |
Why?
| | Cell Line | 1 | 2008 | 2879 | 0.010 |
Why?
| | Age of Onset | 1 | 2004 | 533 | 0.010 |
Why?
| | CD8 Antigens | 1 | 2002 | 76 | 0.010 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 2524 | 0.010 |
Why?
| | Plasma Volume | 1 | 2001 | 20 | 0.010 |
Why?
| | Punctures | 1 | 2001 | 39 | 0.010 |
Why?
| | Antigens, CD | 1 | 2004 | 544 | 0.010 |
Why?
| | Glucagon | 1 | 2002 | 104 | 0.010 |
Why?
| | Chronic Disease | 1 | 2008 | 1811 | 0.010 |
Why?
| | Major Histocompatibility Complex | 1 | 2002 | 234 | 0.010 |
Why?
| | Needles | 1 | 2001 | 63 | 0.010 |
Why?
| | Drainage | 1 | 2001 | 175 | 0.010 |
Why?
| | Safety | 1 | 2001 | 356 | 0.010 |
Why?
| | Alleles | 1 | 2002 | 883 | 0.010 |
Why?
| | Immunity, Innate | 1 | 2004 | 852 | 0.010 |
Why?
| | Obesity | 1 | 2008 | 3000 | 0.010 |
Why?
| | Middle Aged | 1 | 2016 | 34487 | 0.010 |
Why?
| | Mutation | 1 | 2003 | 3999 | 0.010 |
Why?
|
|
Liu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|